Amber Queen, PA
Physician Assistant · Melbourne, FLNPI 1194033860
Payments from drug & device makers
Across 391 payments — averaging $26.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Actelion Pharmaceuticals US, Inc.$1K
- GSK$1K
- Boehringer Ingelheim$762
- Harmony Biosciences LLC$569
- United Therapeutics Corporation$544
- plus $4K from 29 others
What the payments were for
- Food & beverage$10,33099%
- Education$901%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 60 | $1,838 |
| Actelion Pharmaceuticals US, Inc. | 25 | $1,206 |
| GSK | 47 | $1,146 |
| Boehringer Ingelheim | 34 | $762 |
| Harmony Biosciences LLC | 17 | $569 |
| United Therapeutics Corporation | 21 | $544 |
| Regeneron Healthcare Solutions, Inc. | 19 | $493 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $489 |
| Electromed, Inc. | 24 | $405 |
| Amgen | 13 | $317 |
| Philips North America LLC | 15 | $295 |
| Grifols USA, LLC | 10 | $275 |
| Insmed, Inc. | 16 | $241 |
| Jazz Pharmaceuticals Inc. | 9 | $232 |
| Mallinckrodt Hospital Products Inc. | 9 | $204 |
| Inogen, Inc. | 11 | $193 |
| Baxter Healthcare | 9 | $185 |
| Merck | 8 | $181 |
| Pulmonx Corporation | 1 | $140 |
| Inspire Medical Systems, Inc. | 2 | $135 |
| Sanofi | 4 | $95 |
| Genentech USA, Inc. | 4 | $78 |
| Verona Pharma, Inc. | 4 | $77 |
| Penumbra, Inc. | 1 | $65 |
| Avadel CNS Pharmaceuticals, LLC | 2 | $49 |
| Lilly USA, LLC | 2 | $40 |
| Mylan Specialty L.p. | 1 | $32 |
| Resmed Corp | 1 | $22 |
| Advanced Respiratory, Inc | 1 | $20 |
| Boston Scientific | 1 | $18 |
| Johnson & Johnson | 1 | $17 |
| Sandoz | 1 | $17 |
| Fisher & Paykel Healthcare Inc | 1 | $15 |
| Hikma Pharmaceuticals USA | 1 | $14 |
| Phadia US Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UPTRAVI$545
- OPSUMIT$545
- BREZTRI$457
- TRELEGY ELLIPTA$370
- AIRSUPRA$366
- TEZSPIRE$234
- CHARTIS CATHETER$140
- ZEPHYR DELIVERY CATHETER$140
- ZEPHYR ENDOBRONCHIAL VALVE$140
- PULMONX CHARTIS TABLET CONSOLE$140
- FASENRA$116
- Inspire$106
- Prolastin-C Liquid$101
How this compares
$10,420 in reported general payments places this provider in the 95th percentile of 8,062 physician assistant providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UptraviSelexipag | 22 | $482,520 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 212 | $189,196 |
| OpsumitMacitentan | 11 | $129,229 |
| OfevNintedanib Esylate | 16 | $128,602 |
| Pirfenidone | 28 | $127,850 |
| EsbrietPirfenidone | 12 | $125,123 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 93 | $87,478 |
| Advair HfaFluticasone Propion/Salmeterol | 79 | $56,445 |
| Breo ElliptaFluticasone/Vilanterol | 96 | $51,909 |
| Spiriva RespimatTiotropium Bromide | 53 | $50,033 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 38 | $25,397 |
| SymbicortBudesonide/Formoterol Fumarate | 46 | $21,449 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 382 | $17,932 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 20 | $16,884 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 32 | $15,307 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit | $1,206 | $611,74833 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $1,146 | $283,224377 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $762 | $195,51989 claims |
| Genentech USA, Inc.Esbriet | $78 | $125,12312 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $1,838 | $124,234171 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,062 physician assistant providers in Florida.
Other physician assistant in Melbourne
- Richard MarshallPort Orange$988K
- Audrey BeckerSt Augustine$689K
- Kevin WilliamsTampa$647K
- Brian BonomoLecanto$559K
- Melissa SingletonOcala$482K
- Reeli ReinuMaitland$427K
- Jeanelle KingMiami$424K
- Risha BellomoOrlando$397K
- Jason BergerClearwater$344K
- Ashley MillerGainesville$328K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.